Category: Pharma, Life Sciences & Med Tech Players
-
Awaiting potential $1.3B Moderna payout, Arbutus expands Covid-19 patent fight to Pfizer, BioNTech in Canada and UPC
Arbutus and Genevant have filed new lawsuits against Pfizer and BioNTech in Canada and the UPC over lipid nanoparticle patents, days after collecting $178 million from their Moderna settlement.
-
Covid-19 vaccine makers Moderna and Pfizer hit with Sanofi suits over mRNA delivery tech
Sanofi and Translate Bio effectively abandoned their own Covid-19 vaccine effort in 2021 after the former acquired the latter.
-
Munich court finds Illumina infringes Element sequencing patent, orders injunction and product recall
The Munich I Regional Court has found Illumina liable for infringing an Element Biosciences sequencing patent, ordering an injunction, a product recall, and damages, a rare loss for the U.S. sequencing giant.
-
Federal Circuit upholds decision to throw out $107.5M patent infringement verdict against AstraZeneca
The precedential decision, confirming the invalidation of two of Pfizer subsidiary Wyeth’s cancer drug-related patents, held that the plaintiff not only failed to rebut evidence on certain issues, but its own experts agreed against it.
-
UPC Munich LD revokes Promosome’s mRNA patent, dismisses infringement claims against BioNTech, Pfizer over Comirnaty
The UPC’s Munich LD revoked Promosome’s mRNA patent as invalid over prior art and found no infringement by BioNTech and Pfizer’s Comirnaty vaccine, ending the dispute.
-
UPC CoA rejects Guardant’s provisional measures appeal against Sophia Genetics on urgency grounds; reverses added matter finding
The UPC’s CoA has dismissed Guardant Health’s provisional measures appeal over a cancer-detection patent against Sophia Genetics, finding an unexplained three-month gap fatal to urgency, though it reversed the added matter ruling below.
-
Federal Circuit applies Third Circuit law to vacate District of Delaware’s waiver of preliminary injunction bond
The district court made the rare decision to waive Otsuka Pharmaceutical’s requirement to post a bond after granting it a preliminary injunction against Hetero Labs’ generic competitor.
-
FTC urges Fourth Circuit to reverse summary judgment for Johnson & Johnson in Stelara antitrust suit: ‘specific intent not required to prove monopolization’
The U.S. Federal Trade Commission has told the Fourth Circuit that a Virginia court wrongly required proof of specific intent before CareFirst’s Stelara biosimilar-patent monopoly claims against Johnson & Johnson could proceed.
-
Federal Circuit affirms invalidation of Enanta’s Paxlovid-related patent: finds “typo” defense insufficient to fix written description gap in provisional filing
The United States Court of Appeals for the Federal Circuit has affirmed the invalidation of Enanta’s Paxlovid-related patent, rejecting its bid to blame a one-carbon typo in its provisional filing, and leaving Pfizer’s earlier disclosure now free to anticipate the claims.
-
Amgen must pay $20.2 million in damages over antibody patent infringement: District of Delaware jury
Following a trial in the United States District Court for the District of Delaware last week, a jury has found that Amgen’s subsidiary Teneobio has infringed one of competitor Harbour Antibodies’s antibody-related patents and owes over $20 million in damages.